Gene therapies hold extraordinary promise to cure diseases that currently have no effective treatments yet manufacturing bottlenecks and high production costs remain critical barriers to patient access in the United States. ENGINE will design, build, and validate an AI-powered platform that optimizes gene therapy manufacturing processes, dramatically reducing development time and cost. The platform combines advanced computational modeling with AI/ML tools to accelerate process development with fewer experimental cycles and less trial-and-error. Scalable across the biopharmaceutical industry, ENGINE will empower developers and manufacturers of all sizes to bring disease-modifying and curative gene therapies to American patients faster and more affordably.